StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report issued on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.
Separately, Lake Street Capital dropped their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.
Get Our Latest Research Report on Evogene
Evogene Stock Performance
Evogene (NASDAQ:EVGN – Get Free Report) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.
Institutional Investors Weigh In On Evogene
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Stories
- Five stocks we like better than Evogene
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- CD Calculator: Certificate of Deposit Calculator
- Applied Materials Market Capitulates: Now is the Time to Buy
- What is the NASDAQ Stock Exchange?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.